All News
RA-ILD: an update
Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.
Read Article
Where are we with treating Pre-Rheumatoid Arthritis?
The ability to prevent RA in individuals at risk is a holy grail in rheumatology. There is a long history dating back to the PROMPT trial of methotrexate and PRAIRIE trial of rituximab. Both otrials showed an effect, but it seemed more likely to be a delaying of RA than prevention or modulation. Framing it another way, there were better outcomes in pre-RA because we were actually treating RA as it emerged with a proven effective treatment. It is in this setting that three trials of ongoing studies in RA preventative therapy are presented at ACR.
Read Article
Schieir et al. Women with early RA less likely to achieve remission. 12 months 37% vs 43%. 4 years 61% vs 64%. Time to remission 19 months vs 16 months. @RheumNow #ACR22 Abstr#0532 https://t.co/ZRuqqaPHHU https://t.co/pDBHHtLEhs
Richard Conway RichardPAConway ( View Tweet)
🧨Late breaking abstract🧨 #ACR22 @RheumNow #ACRbest
Identifying fetal myocardial targets in congenital heart block (CHB)
Abstract #L13
đź«€maternal serum underwent mass spec. that identified Ab to 4 protein targets that predicted CHB including anti-ATP1A1 as early as 7w
Catherine Sims, MD DrCassySims ( View Tweet)
Porter et al. Asymptomatic Pre-RA to symptomatic Pre-RA to early RA steady increase in bacterial infection compared to HC. Causality or Reverse Causality? I think more likely reverse - disease related immunosuppresion @RheumNow #ACR22 Abstr#0535 https://t.co/i5iN3Db7rf https://t.co/2ynYF7Vqbl
Richard Conway RichardPAConway ( View Tweet)
Ab0674 #ACR22 HIT AND APLS??
Retrosp review of 23 pts treated for HIT in the hospital with APLS or SLE with aPL Ab:
Not one ultimately met clinical criteria for HIT
1 pt had PF4 antibodies, SRA testing negative in ALL cases
Thrombocytopenia w/ aPL Abs? Think APS 1st!
@Rheumnow https://t.co/ZYZP5VZF0R
Eric Dein ericdeinmd ( View Tweet)
Ab0673 #ACR22 Occurrence & Severity of ITP w or w/o APLS antibodies
Fewer bleeding events in ITP patients w/ aPL antibodies (15% vs 43%) compared to w/o aPL antibodies
Despite more use of a/c and lower median patients in aPL patients
Is aPL Ab a good prognosis for ITP?
@RheumNow https://t.co/yLBVUN2T0L
Eric Dein ericdeinmd ( View Tweet)
Hear Dr. @AngusWorthing discuss advocacy and more legislative updates at #ACR22 @RheumNow https://t.co/zD8xpcCzi2
Dr. Rachel Tate uptoTate ( View Tweet)
IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in
â—¦ total spinal pain (SP)
â—¦ nocturnal SP
â—¦ morning stiffness (BASDAI)
â—¦ fatigue (FACIT-F)
Deodhar et al, BE MOBILE 1,2 Abst 0409 https://t.co/vpCrG2COuB
#ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Fava et al. Urinary biomarkers at 3 months better than UPCR in predicting 12 month treatment response in SLE nephritis . CD163 AUC 0.83 vs 0.75 for UPCR @THKC1 @RheumNow #ACR22 Abstr#0536 https://t.co/YI3JC2uKcv https://t.co/jnkfbI0Z1M
Richard Conway RichardPAConway ( View Tweet)
Here is a quick recap on #ACR22 Abstr#0355 Effect of voclosporin in class V lupus nephritis #lupus https://t.co/0cR8On5UWN via @YouTube @RheumNow https://t.co/E25so6X2fj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Wilson et al. Sputum ACPA or RF assoc RA development in serum ACPA+ individuals. x4 more likely - 46% vs 12%. @RheumNow #ACR22 Abstr#0533 https://t.co/7kpeXWjeKI https://t.co/Sx41DOJAAX
Richard Conway RichardPAConway ( View Tweet)
Please do catch up on my interview with Dr Amit Saxena, New York on their work. #ACR22 Abstr#2081 Breakthrough COVID infection in SLE during Omicron era https://t.co/4dINWSobxj via @YouTube @RheumNow https://t.co/hIHWGRcu5h
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Riskedal et al. DNA methyllation based biomarker for sero- RA. Accurary 1.0 for sero+ RA and reactive arthritis, 0.75 sero-RA, 0.5 PsA. Promising but not there yet. @RheumNow #ACR22 Abstr#0531 https://t.co/clLR0V33WJ https://t.co/7Hts9gtkW9
Richard Conway RichardPAConway ( View Tweet)
Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. Abs 0974 #ACR22 @RheumNow https://t.co/FeYrdlwQsA
Dr. Rachel Tate uptoTate ( View Tweet)
Gomez et al. Predictors renal flare in SLE. Adjusted models - low C3, low albumin, proteinuria. @RheumNow #ACR22 Abstr#0540 https://t.co/POfeAa9Ao9 https://t.co/a3JkSP1MkX
Richard Conway RichardPAConway ( View Tweet)
In-person meetings are tough. Virtual meetings are tough. But hybrid meetings are logistical nightmares
Would've liked better WiFi and a live poster hall, but a HUGE credit to @ACRheum on planning a great #ACR22 hybrid meeting. Really amazing job
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Getting to know the COVID-19 drugs:
â—¦ Pre-exposure prophylaxis: Tixagevimab and cilgavimab (Evusheld)
â—¦ Post-exposure treatments: Paxlovid (po), Molnupiravir (po), Sotrovimab (IV), Remdesivir (IV)
Rachael Perritt, COVID-19, #ACR22 @RheumNow https://t.co/bCwxJ9YfIU
Dr. Antoni Chan synovialjoints ( View Tweet)
Show us how you ACR! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/aAUyhmrLPW
Dr. John Cush RheumNow ( View Tweet)
Trend of reduced opioid use when initiating biologics and JAKi in RA though effect size small and very high baseline use (>50%) in this insurance claims database.
Residual pain and harm minimisation still areas of need.
@RheumNow #ACR22 ABST0925
https://t.co/XGHu0fIMF0 https://t.co/PutNNQiKnY
Julian Segan JulianSegan ( View Tweet)